| 000 | 01787 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515085935.0 | ||
| 264 | 0 | _c20080328 | |
| 008 | 200803s 0 0 eng d | ||
| 022 | _a1468-3288 | ||
| 024 | 7 |
_a10.1136/gut.2007.129478 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPersico, M | |
| 245 | 0 | 0 |
_aElevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. _h[electronic resource] |
| 260 |
_bGut _cApr 2008 |
||
| 300 |
_a507-15 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aCell Line, Transformed |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGene Expression Profiling _xmethods |
| 650 | 0 | 4 | _aGenetic Markers |
| 650 | 0 | 4 | _aHaplotypes |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aRNA, Messenger _xgenetics |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aSuppressor of Cytokine Signaling 3 Protein |
| 650 | 0 | 4 |
_aSuppressor of Cytokine Signaling Proteins _xblood |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aCapasso, M | |
| 700 | 1 | _aRusso, R | |
| 700 | 1 | _aPersico, E | |
| 700 | 1 | _aCrocè, L | |
| 700 | 1 | _aTiribelli, C | |
| 700 | 1 | _aIolascon, A | |
| 773 | 0 |
_tGut _gvol. 57 _gno. 4 _gp. 507-15 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/gut.2007.129478 _zAvailable from publisher's website |
| 999 |
_c17406120 _d17406120 |
||